COMBINATION OF AZILSARTAN MEDOXOMIL AND CHLORTHALIDONE: IS IT POSSIBLE TO FIGHT SYSTEMIC HYPERTENSION AND OBESITY TOGETHER?
https://doi.org/10.15829/1560-4071-2017-8-102-106
Abstract
Arterial hypertension (AH) and obesity are the main risk factors of chronic noncommunicable diseases. Adipous tissue is not only a depot for energetic compounds, but is an active endocrine organ synthetizing biologically active substances that facilitate development of AH. Patients with AH and obesity are in the high cardiovascular risk group and demand effective combination antihypertension therapy. One of such drugs is the fixed combination of azilsartan medoxomil and chlorthalidone, which safety and efficacy are confirmed by various trials. Our clinical case demonstrates positive action of Edarbi Сlo on office and 24-hour blood pressure (BP), main parameters of aorta stiffness and structural and functional condition of myocardium at rest, as in exertion in patient with AH and obesity.
About the Authors
Yu. A. Vasyuk
A. I. Evdokimov Moscow State University of Medicine and Dentistry (MSUMD)
E. Yu. Shupenina
A. I. Evdokimov Moscow State University of Medicine and Dentistry (MSUMD)
Russian Federation
Russian Federation
E. A. Nesterova
A. I. Evdokimov Moscow State University of Medicine and Dentistry (MSUMD)
E. I. Golubkova
A. I. Evdokimov Moscow State University of Medicine and Dentistry (MSUMD)
V. V. Nesvetov
A. I. Evdokimov Moscow State University of Medicine and Dentistry (MSUMD)
References
1. Boytsov SA, Chuchalin AG, Arutyunov GP, et.al. Prevention of chronic non-infectious diseases. Guidelines. Moscow 2013; 136 (Бойцов С.А., Чучалин А.Г., Арутюнов Г.П. и соавт. Профилактика хронических неинфекционных заболеваний. Рекомендации. Москва 2013 г., 136 с).
2. Mancia G, Fagard R, Narkieewicz R, et.al. The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and the European Society of Cardiology (ESC). 2013 ESH/ESC Guidelines for the management of arterial hypertension. J. Hypertens. 2013; 31: 1281-1357.
3. Boytsov SA, Balanova YuA, Shalnova SA, et.al . Arterial hypertension among individuals of 25–64 years old: prevalence, awareness, treatment and control. By the data from ECCD. Cardiovascular therapy and prophylaxis 2014;13(4):4–14. (Бойцов С.А., Баланова Ю.А., Шальнова С.А. и соавт. Артериальная гипертония среди лиц 25-64 лет: распространенность, осведомленность, лечение и контроль. По материалам исследования ЭССЕ. Кардиоваскулярная терапия и проф. 2014 13(4):4-14).
4. Yumuk V, Tsigos C, Fried M, et al. European Guidelines for Obesity Management in Adults. Eur. J. Obes. 2015; 8:402-424.
5. Balanova YuA, Kontsevaia AV, Shalnova SA, et.al. Prevalence of behavioral risk factors for cardiovascular disease in the Russian population: Results of the ESSE-RF epidemiological study. Preventive Medicine 2014; 5:42-52 (Баланова Ю. А., Концевая А. В., Шальнова С. А. и соавт. Распространенность поведенческих факторов риска сердечно-сосудистых заболеваний в российской популяции по результатам исследования ЭССЕ-РФ. Профилактическая медицина 2014; 5: 42-52).
6. Balarini C, Braga V. New Translational Insights on Metabolic Syndrome: Obesity, Hypertension, Diabetes and Beyond. Front. Phisiol. 2016; 10 (7):229.
7. Delarue J, Magnan C. Free fatty acids and insulin resistance. Curr. Opin. Clin. Nutr. Metab. Care 2007; 10(2):142-8.
8. Shirani J., Sarin S, Wenger C. et.al. Clinical significance of epicardial fat measured using cardiac multislice computed tomography. Am. J. Cardiol. 2008; 102(6):767-71.
9. Wald D, Law M, Morris J, et al. Combination therapy versus monotherapy in reducing blood pressure; meta-analysis on 11,000 participants from 42 trials. Am J Med 2009; 122:290-300.
10. Gupta A, Arshad S, Poulter N. Compliance, safety, and effectiveness of fixed-dose combinations of antihypertensive agents: a meta-analysis. Hypertension 2010; 55:399-407.
11. Sica D, White W, Weber M, et.al. Comparison of the novel angiotensin II receptor blocker azilsartan medoxomil vs valsartan by ambulatory blood pressure monitoring. J. Clin. Hypertens. 2011; 13(7): 467-72.
12. Rakugi H, Enya K, Suqiura K, et al. Comparison of the efficacy and safety of azilsartan with that candesartan cilexetil in Japanese patients with grade I-II essential hypertension: a randomized, double-blind clinical study. Hypertens. Res. 2012; 35(5):552-8.
13. Bönner G, Bakris G, Sica D, et.al. Antihypertensive efficacy of the angiotensin receptor blocker azilsartan medoxomil compared with the angiotensin-converting enzyme inhibitor ramipril. J. Hum. Hypertens. 2013; 27(8):479-86.
14. Vasyuk YuA, Shupenina EYu, Nesterova EA. Azilsartan medoxomil capabilities in arterial hypertension and obesity: clinical case. Cardiology 2016; 11(56):108-112 (Васюк Ю.А., Шупенина Е.Ю., Нестерова Е.А. и соавт. Возможности азилсартана медоксомила при артериальной гипертонии и ожирении: случай из практики. Кардиология 2016; 11(56):108-112).
15. Iwai M, Chen R, Imura Y, et al. TAK-536, a new AT1 receptor blocker, improves glucose intolerance and adipocyte differentiation. Am. J. Hypertens. 2007; 20:579-586.
16. Zhao M, Li Y, Wang J, et.al. Azilsartan treatment improves insulin sensitivity in obese spontaneously hypertensive Koletsky rats. Diabetes Obes. Metab. 2011; 13(12): 1123-9.
17. Hye Khan M, Neckar J, Cummens B, et al. Azilsartan decreases renal and cardiovascular injury in the spontaneously hypertensive obese rat. Cardiovasc. Drugs Ther. 2014; 28(4):313-22.
18. Tarikuz Zaman A, McLean D, Sobel B. The efficacy and tolerability of azilsartan in obese insulin-resistant mice with left ventricular pressure overload. J. Cardiovasc. Pharmacol. 2013; 62(4):381-7.
19. Akram J, Sheikh U, Mahmood M, et al. Antihypertensive efficacy of indapamide SR in hypertensive patients uncontrolled with a background therapy: the NATIVE study. Curr Med Res Opin 2007; 23:2929–2936.
20. Wright JT, Jr. Harris-Haywood S, Pressel S, et al. Clinical outcomes by race in hypertensive patients with and without the metabolic syndrome: Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Arch Intern Med 2008;168:207-217.
21. Jin Ch, Jeon Y, Kleven D, et al. Combined endothelin A blockade and chlorthalidone treatment in a rat model of metabolic syndrome. J. Pharmacol. and Experim. Ther. 2014; 351:467-473.
22. Dorsch M, Gillespie B, Erickson S, et al. Chlorthalidone reduces cardiovascular events compared with hydrochlorothiazide: a retrospective cohort analysis. Hypertension 2011; 57:689-9421.
23. Ernst M, Carter B, Goerdt C, et al. Comparative antihypertensive effects of hydrochlorothiazide and chlorthalidone on ambulatory and office blood pressure. Hypertension 2006; 47:352-8.
24. Ernst M, Carter B, Zheng S, et al. Meta-analysis of dose-response characteristics of hydrochlorothiazide and chlorthalidone: effects on systolic blood pressure and potassium. Am J Hypertens 2010; 23:440-6.
25. Sica D, Bakris G, White W, et al. Blood pressure-lowering efficacy of the fixed-dose combination of azilsartan medoxomil and chlorthalidone: a factorial study. J Clin Hypertens (Greenwich) 2012; 14:284-92.
26. Bakris G, Sica D, White W, et al. Antihypertensive efficacy of hydrochlorothiazide vs chlorthalidone combined with azilsartan medoxomil. Am J Med 2012; 125:1229.
27. Cushman W, Bakris G, White W, et al. Azilsartan medoxomil plus chlorthalidone reduces blood pressure more effectively than olmesartan plus hydrochlorothiazide in stage 2 systolic hypertension. Hypertension 2012; 60:310-18.
Review
For citations:
Vasyuk Yu.A., Shupenina E.Yu., Nesterova E.A., Golubkova E.I., Nesvetov V.V. COMBINATION OF AZILSARTAN MEDOXOMIL AND CHLORTHALIDONE: IS IT POSSIBLE TO FIGHT SYSTEMIC HYPERTENSION AND OBESITY TOGETHER? Russian Journal of Cardiology. 2017;(8):102-106. (In Russ.) https://doi.org/10.15829/1560-4071-2017-8-102-106
Views:
795
Email this article 